济民健康管理股份有限公司: 关于济民健康管理股份有限公司 股票交易异常波动的征询函的回函 股票交易异常波动的征询函的回函 本公司持有济民健康管理股份有限公司 24. 37%的股份,为济民健康管理股 份有限公司控股股东。 本公司于 2025 年 8 月 26 日收到你公司发来的《关于济民健康管理股份有 限公司股票交易异常波动的征询函》,现就你公司征询事项回复如下: 一、本公司不涉及你公司的应披露而未披露的重大信息,不存在针对你公司 的重大资产重组、发行股份、上市公司收购、债务重组、业务重组、资产剥离和 资产注入等重大事项。 二、无其他重大事项。 (以下无正文) 此页无正文,为《关于济民健康管理股份有限公司股票交易异常波动的征询函的 回函》之盖章页) 双鸽集团有限公司。 2025年8月26日/ 关于济民健康管理股份有限公司 济民健康管理股份有限公司: 本家族成员直接持有济民健康管理股份公司(以下简称"公司")股份 7,727.70 万股,占公司总股本的 14.72%,并持有公司控股股东双鸽集团有限公 司 100%的股权和法人股东台州市梓铭贸易有限公司 100%的股权，为公司实际控 制人。 本家族全体成员于 202 ...

证券代码：603222 证券简称：济民健康 公告编号：2025-041 济民健康管理股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 济民健康管理股份有限公司（以下简称"公司"）股票于 2025 年 8 月 22 日、 8 月 25 日、8 月 26 日连续三个交易日内收盘价格跌幅偏离值累计达到 20%，根据 《上海证券交易所交易规则》的相关规定，属于股票交易异常波动。 二、公司关注并核实的相关情况 ●公司股票交易于2025年8月22日、8月25日、8月26日连续三个交易日内收盘 价格跌幅偏离值累计超过20%，属于《上海证券交易所交易规则》规定的股票交易 异常波动情形。 ●经公司自查并书面征询控股股东及实际控制人，截至本公告披露日，公司 不存在应披露而未披露的重大事项。 ●公司敬请广大投资者注意二级市场交易风险、经营业绩风险，敬请广大投 资者理性决策，审慎投资。 一、股票交易异常波动的具体情况 针对股票交易异常波动情况，公司对有关事项进行了核查，现将有关情况说 明如 ...

济民健康(603222)今日下跌7.68%，全天换手率19.33%，成交额9.45亿元，振幅6.25%。龙虎榜数据显 示，营业部席位合计净卖出1778.77万元。 上交所公开信息显示，当日该股因日跌幅偏离值达-7.30%上榜，营业部席位合计净卖出1778.77万元。 济民健康8月26日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 广发证券股份有限公司南京汉中路证券营业部 | 3164.12 | | | 买二 | 国泰海通证券股份有限公司总部 | 981.70 | | | 买三 | 中国银河证券股份有限公司烟台证券营业部 | 876.64 | | | 买四 | 东方财富证券股份有限公司拉萨团结路第一证券营业部 | 868.13 | | | 买五 | 首创证券股份有限公司长沙滨江路证券营业部 | 836.40 | | | 卖一 | 浙商证券股份有限公司杭州五星路证券营业部 | | 2267.34 | | 卖二 | 中信证券股份有限公司浙江分公司 | 1929.66 | | - ...

Group 1: Company Performance - CanSino reported a revenue of 382 million yuan for the first half of 2025, a year-on-year increase of 26%, with a net loss of 13.49 million yuan, narrowing by 94.02% compared to a loss of 225 million yuan in the same period last year [1] - Wantai Bio disclosed a revenue of 844 million yuan, a year-on-year decrease of 38.25%, resulting in a net loss of 144 million yuan, indicating a shift from profit to loss due to market adjustments and government procurement impacts [2] - Jimin Health reported a revenue of 366 million yuan, a year-on-year decline of 21.30%, with a net loss of 52.70 million yuan, compared to a profit of 25.44 million yuan in the previous year [3] - ST Noratech achieved a revenue of approximately 1.048 billion yuan, a year-on-year increase of 26.07%, with a net profit of about 310 million yuan, reflecting a growth of 36.49% [5] Group 2: Market Trends and Insights - The vaccine industry is facing challenges such as intensified competition and insufficient demand, leading to performance pressure on several companies, including CanSino and Zhifei Biological [2] - Jimin Health's stock experienced a significant increase of 53.78% over a short period, indicating potential market overreaction and speculative trading [3][4] - The demand for peptide raw materials, particularly GLP-1 related products, has driven ST Noratech's performance, highlighting a strong market for specific pharmaceutical segments [5] Group 3: Shareholder Actions - TBP 3Doctors (HK) Limited plans to reduce its stake in Sanbo Brain Science by up to 6.09 million shares, representing 3% of the total share capital, which may signal a lack of confidence in the company's future prospects [6]

Group 1: 康希诺 (CanSino) - The company reported a revenue of 382 million yuan for the first half of 2025, a year-on-year increase of 26% [1] - The net profit attributable to shareholders was a loss of 13.49 million yuan, significantly narrowing from a loss of 225 million yuan in the same period last year, a reduction of 94.02% [1] - Sales revenue from two types of combined meningococcal vaccines reached approximately 364 million yuan, up 38.43% year-on-year [1] Group 2: 万泰生物 (Wantai Bio) - The company reported a revenue of 844 million yuan for the first half of 2025, a year-on-year decrease of 38.25% [2] - The net profit attributable to shareholders turned into a loss of 144 million yuan, compared to a profit in the same period last year [2] - The revenue decline was attributed to market adjustments, government procurement, and the expansion of the nine-valent HPV vaccine age group, leading to lower-than-expected sales [2] Group 3: 济民健康 (Jimin Health) - The company reported a revenue of 366 million yuan for the first half of 2025, a year-on-year decrease of 21.30% [3] - The net profit was a loss of approximately 52.70 million yuan, compared to a profit of 25.44 million yuan in the same period last year [3] - The stock price saw a cumulative increase of 53.78% from August 13 to August 19, with a trading halt on August 20, indicating potential market overreaction [3] Group 4: ST诺泰 (ST Novartis) - The company reported a revenue of approximately 1.048 billion yuan for the first half of 2025, a year-on-year increase of 26.07% [4] - The net profit attributable to shareholders was approximately 310 million yuan, an increase of 36.49% year-on-year [4] - The revenue growth was primarily driven by significant sales increases in peptide raw materials, particularly GLP-1 related products [4] Group 5: 三博脑科 (Sanbo Brain Science) - The shareholder TBP3Doctors (HK) Limited plans to reduce its holdings by up to approximately 6.09 million shares, accounting for 3% of the total share capital [5] - The reduction will occur through centralized bidding and block trading within three months after the announcement [5] - The shareholder's decision to reduce holdings may signal a lack of confidence in the company's future development prospects [5]

Core Viewpoint - The article discusses the current market conditions in A-shares, highlighting sector performance and investment strategies for new investors in a slow bull market [3][5][6]. Group 1: Market Performance - On August 26, A-shares opened lower but turned positive in the afternoon, with artificial intelligence and computing power sectors leading the gains [3]. - Notable stocks such as Kaipu Cloud, Tuo Wei Information, and Tianrongxin hit the daily limit up, reflecting strong investor confidence in domestic AI development [3]. - The gaming sector also performed well, with 173 games approved in August, marking a new high for the year [3]. - Chip stocks faced adjustments, with companies like Chip Origin and Cambrian experiencing significant declines [3]. Group 2: Investment Strategies - Investors are advised to recognize that the current slow bull market is characterized by structural differentiation and sector rotation, with only 30% of leading stocks likely to continue performing well [5]. - Four core principles for new investors include embracing long-term investment, utilizing professional tools for decision-making, adhering to strict risk control measures, and maintaining a positive mindset [5][6]. - The article emphasizes the importance of avoiding the traps of seeking quick profits, over-concentration in single stocks, and using leverage [6].

Group 1 - The innovative drug concept stocks are experiencing a downturn, with multiple companies such as Guangshengtang, Yuandong Biological, Yangguang Nuohuo, Haitai Biological, Rejing Biological, Kailaiying, Lifang Pharmaceutical, and Jimin Health seeing declines of over 5% [1]

Group 1 - The A-share market opened lower on August 26, with the Shanghai Composite Index down 0.36%, the Shenzhen Component Index down 0.09%, and the ChiNext Index down 0.69%, with over 2800 stocks declining across the market [1] - The artificial intelligence and computing power sectors showed strong performance, with stocks like Kaipu Cloud and Tuowei Information hitting the daily limit, driven by breakthroughs in domestic AI models and improvements in domestic AI chips [1] - The gaming sector performed well, with companies like 37 Interactive Entertainment and Perfect World seeing significant gains, following the approval of 173 games by the National Press and Publication Administration, marking a new high for the year [1] Group 2 - Chip stocks experienced a downturn, with companies like Chipone Technology and Cambricon falling over 7% and 3% respectively, indicating a potential adjustment in the semiconductor sector [2] - The innovative drug sector saw a slight pullback, with companies like Jimin Health and Shunlian Bio dropping over 3%, although the industry is expected to shift from capital-driven to profit-driven growth by 2025 [2] Group 3 - Investment advisors suggest that new investors should approach the stock market cautiously, recognizing that the current slow bull market is characterized by structural differentiation and sector rotation, with only 30% of leading stocks likely to continue performing well [3] - Four core principles for new investors include embracing long-term investment, utilizing professional tools for decision-making, adhering to strict risk control measures, and maintaining a positive mindset to improve long-term success rates [4]

Market Overview - A-shares experienced a collective decline with the Shanghai Composite Index down 0.36%, the Shenzhen Component Index down 0.09%, and the ChiNext Index down 0.69% as of 10:30 AM, with over 2800 stocks declining in total [1]. Gaming Sector - The gaming sector showed resilience with stocks like 37 Interactive Entertainment hitting the daily limit, and companies such as Kaixin Network, Perfect World, and Giant Network also seeing gains. The National Press and Publication Administration announced the approval of 173 games in August 2025, including 166 domestic and 7 imported titles, marking a new high for the year [2]. Semiconductor Sector - The semiconductor sector faced adjustments, with companies like Chipone Technology falling over 7% and Cambricon Technologies down over 3%. Other companies such as Yuntian Lifeng and Haiguang Information also experienced declines. The innovative drug sector saw slight pullbacks, with Ji Min Health and Shunlian Bio dropping over 3%. According to Xiangcai Securities, the domestic innovative drug industry is expected to reach a turning point in 2025, shifting from capital-driven to profit-driven growth, with ongoing support from fundamentals and policies likely to continue the trend of performance and valuation recovery [3]. Investment Guidelines - In the current market context, investment advisory institutions suggest that novice investors should proceed with caution and fully understand the market conditions before engaging in stock investments. The director of Guangdong Bozhong Dayang Financial Research Institute, Wu Zhihui, emphasizes that the current slow bull market is characterized by structural differentiation and sector rotation, where only 30% of leading stocks may continue to strengthen, 40% may remain stagnant, and the remaining 30% could experience declines. Wu recommends four core principles for novice investors: 1. Abandon the idea of "getting rich overnight" and embrace long-termism, avoiding the traps of chasing themes, trading small caps, and using leverage. 2. Utilize professional tools for informed decision-making, avoiding blind following of trends, especially in the face of uncertainties. 3. Strictly adhere to risk control rules, including maintaining appropriate position sizes, setting stop-loss lines, and avoiding leverage and speculative stocks. 4. Maintain a mindset that influences long-term success, focusing on cultivating investment habits during this slow bull market and shifting from frequent short-term trading to a philosophy of weekly reviews and deepening industry logic [5].

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688656 | 浩欧博 | 125.39 | -9.01% | 4.35万 | 5.67亿 | | 603222 | 济民健康 | 68.6 | -3.61% | 100.18万 | 9.90亿 | | 688677 | 海泰新光 | 45.81 | -2.70% | 4.36万 | 1.9867 | | 688351 | 微电生理 | 25.84 | -2.16% | 8.55万 | 2.21亿 | | 300049 | 福瑞股份 | 63.20 | -1.74% | 20.41万 | 12.99 Z | | 688016 | 心脉医疗 | 119.19 | -1.58% | 4.30万 | 5.11亿 | | 300289 | 利德曼 | 9.08 | -1.30% | 37.97万 | 3.48亿 | | 688613 | 奥精医疗 | 20.68 | -1.15% | 4.92万 | 1.03亿 | | 300633 | 开立医疗 | + ...